目的：对芬吗通治疗女性更年期综合症患者的临床疗效和安全性进行研究。方法：例选更年期综合症患者108例，随机分为对照组和治疗组，每组各54名。对照组给予戊酸雌二醇片，治疗组给予芬吗通，连续服用16周，比较治疗前后两组患者的临床疗效、改良的Kupperman评分及主要症状变化情况；检测治疗前后两组患者的血清指标变化情况。结果：随访结束后，对照组和治疗组的临床疗效总有效率分别为77.8%和88.9%，两组总有效率差异显著(P<0.05)；两组患者治疗后的Kupperman评分相对治疗前均显著降低(P<0.05)；随访结束后，对照组和治疗组患者的更年期症状均得到有效改善(P<0.05)，治疗组患者一些症状更是得到极显著的好转(P<0.01)，且两组间的变化具有统计学差异(P<0.05)；1年后两组患者血清中雌二醇(serum estradiol，E2)水平明显升高，促黄体激素(luteinizing hormone，LH)水平明显降低，组间无统计学差异；两组患者促卵泡激素(folliclestimulating hormone，FSH)水平明显下降，且治疗组显著低于对照组(P<0.05)；随访结束后，治疗组血清总胆固醇(total serum cholesterol，TG)，甘油三酯(triglycerides，TC)，低密度脂肪酸(lowdensity fatty acids，LDL-C)均较治疗前明显下降，并低于对照组(P<0.05或P<0.01)，高密度脂肪酸(high density fatty acid increased，HDL-C)明显上升，并高于对照组(P<0.05)。两组患者不良反应率比较差异无统计学意义(P>0.05)。结论：芬吗通能有效改善更年期女性的内分泌水平及临床症状。
Clinical research on the treatment of climacteric syndrome by femoston
Objective: To study the clinical efficacy and safety on the treatment of female climacteric syndrome (CS) by Femoston. Methods: A total of 108 cases of CS patients were selected and randomly divided into two groups, the control group and treatment group, each group had 54 cases. The control group was treated with estradiol vale rate, and the treatment group was treated with Femoston, continue taking for 16 weeks, and then compared the clinical effect, Kupperman score, the change of main symptom integral and detected the change of serum indicators. Results: After the end of the follow-up, the total clinical effective rate of the control group and treatment group were 77.8% and 88.9% respectively, the differences between two groups were significantly (P<0.05). Before and after treatment, the Kupperman score was significantly reduced (P<0.05), menopausal symptoms of the both group were effectively improved (P<0.05), and statistically difference also between the two groups (P<0.05). After one year, the serum estradiol (E2) levels of both group increased significantly, the luteinizing hormone (LH) levels of both group reduced significantly, but no statistical difference between two groups (P>0.05). The follicle stimulating hormone (FSH) level declined obviously, and the treatment group was significantly lower than the control group (P<0.05). After the end of the follow-up, the treatment group total serum cholesterol (TG), triglycerides (TC), low density fatty acids (LDL-C) were markedly reduced, and lower than the control group (P<0.05 or P<0.01), high density fatty acid increased (HDL-C) was markedly increased, and higher than the control group (P<0.05). There was no significant difference in the adverse reaction rate between the two groups (P>0.05). Conclusion: Femoston can effectively improve the endocrine level and clinical symptoms for the menopausal women.